Skip to main content
. 2016 Feb 4;23:24. doi: 10.1186/s12929-016-0242-7

Fig. 6.

Fig. 6

Expression patterns of soluble urokinase-type plasminogen activator receptor (suPAR) variants in clinical subjects. Immunoblot analyses of expressions of serum suPAR variants in minimal-change disease (MCD) and focal segmental glomerulosclerosis (FSGS) clinical subjects are presented